Red X iconGreen tick iconYellow tick icon

Chris PembertonResearch Professor

Email chris.pemberton@otago.ac.nz

Christchurch Heart Institute
Department of Medicine
University of Otago, Christchurch
PO Box 4345
Christchurch 8140
New Zealand

Current roles

  • Director, Translational Biodiscovery Laboratory, Christchurch Heart Institute
  • Named Investigator on the current Christchurch Heart Institute HRC Programme grant.
  • Principal Investigator on HRC, MBIE and WADA funded signal peptide projects
  • Research Professor, Department of Medicine

Research interests

  • Novel protein/peptide biomarker identification and measurement
  • Cardioendocrine signalling in the circulation and heart tissue
  • Ex vivo study of novel cardiovascular diagnostic and therapeutic agents
  • Commercialisation of biomedical technologies

Awards and professional memberships

  • 2012- Research Commercialisation – Strategic and Implementation Committee, Division of Health Sciences.
  • 2012- Corresponding Member, Canterbury, NZ Society of Endocrinology
  • 2011 Health Research Council of New Zealand Liley Medal
  • 2011- European Society for Cardiology, Working Group on Cellular Biology of the Heart
  • 2010- American Association of Clinical Chemistry
  • 2007-11 Health Research Council of New Zealand Sir Charles Hercus Fellowship
  • 2006-2009 Treasurer, Executive Committee Member, NZ Society of Endocrinology

Publications

Ocariza, M. G. C., Paton, L. N., Tang, W. H. W., Templeton, E. M., Pilbrow, A. P., Pemberton, C. J., & Appleby, S. (2024). CNDP2 is a potential modulator of heart failure outcomes. Proceedings of the 17th GeneMappers Conference. Retrieved from https://www.genemappersconference.org Conference Contribution - Published proceedings: Abstract

Paterson, M. A., Pilbrow, A. P., Frampton, C. M. A., Cameron, V. A., Troughton, R. W., Pemberton, C. J., … Richards, A. M., … Palmer, B. R. (2024). Plasma soluble fms-like tyrosine kinase-1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure. European Journal of Heart Failure. Advance online publication. doi: 10.1002/ejhf.3368 Journal - Research Article

Pirker, T., Adamson, P., Pemberton, C., Pham, T., & Chew-Harris, J. (2024). Novel preservation of cardiac mitochondrial integrity by suPAR following anoxia-reoxygenation injury. Heart, Lung & Circulation, 33(Suppl. 2), (pp. S69-S70). doi: 10.1016/j.hlc.2024.04.247 Conference Contribution - Published proceedings: Abstract

Montecillo, J., Troughton, R., Pemberton, C., & Chew-Harris, J. (2024). Removal of glycosylation improves performance of soluble urokinase plasminogen activator receptor (suPAR) levels for acute decompensated heart failure diagnosis. Heart, Lung & Circulation, 33(Suppl. 2), (pp. S58). doi: 10.1016/j.hlc.2024.04.218 Conference Contribution - Published proceedings: Abstract

Pickering, J., Kavsak, P., Christenson, R., Troughton, R., Pemberton, C., Richards, M., Joyce, L., & Than, M. (2024). High-sensitivity troponin assays are safe to rule-out myocardial infarction even if they have high imprecision. Heart, Lung & Circulation, 33(Suppl. 2), (pp. S76). doi: 10.1016/j.hlc.2024.04.261 Conference Contribution - Published proceedings: Abstract

Back to top